{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:41:29Z","timestamp":1784421689385,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12432-6","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T11:12:38Z","timestamp":1753269158000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-4781","authenticated-orcid":false,"given":"Sabina","family":"Ugov\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreja Rehberger","family":"Likozar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Levstek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina Trebu\u0161ak","family":"Podkraj\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janja","family":"Zupan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slobodan","family":"Antoni\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miran","family":"\u0160ebe\u0161tjen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,23]]},"reference":[{"key":"12432_CR1","doi-asserted-by":"publisher","first-page":"5880","DOI":"10.3390\/ijms22115880","volume":"22","author":"C Barale","year":"2021","unstructured":"Barale, C., Melchionda, E., Morotti, A. & Russo, I. PCSK9 biology and its role in atherothrombosis. Int. J. Mol. Sci. 22, 5880. https:\/\/doi.org\/10.3390\/ijms22115880 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"12432_CR2","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1161\/ATVBAHA.111.240549","volume":"32","author":"E Chernogubova","year":"2012","unstructured":"Chernogubova, E. et al. Common and low-frequency genetic variants in the PCSK9 locus influence Circulating PCSK9 levels. Arterioscler. Thromb. Vasc. Biol. 32, 1526\u20131534. https:\/\/doi.org\/10.1161\/ATVBAHA.111.240549 (2012).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"12432_CR3","doi-asserted-by":"publisher","first-page":"909","DOI":"10.5551\/jat.55400","volume":"27","author":"E Yurtseven","year":"2020","unstructured":"Yurtseven, E., Ural, D., Baysal, K. & Tokg\u00f6zo\u011flu, L. An update on the role of PCSK9 in atherosclerosis. J. Atheroscler. Thromb. 27, 909\u2013918. https:\/\/doi.org\/10.5551\/jat.55400 (2020).","journal-title":"J. Atheroscler Thromb."},{"key":"12432_CR4","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc, G. et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in Familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24, 1454\u20131459. https:\/\/doi.org\/10.1161\/01.ATV.0000134621.14315.43 (2004).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"12432_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154\u2013156. https:\/\/doi.org\/10.1038\/ng1161 (2003).","journal-title":"Nat. Genet."},{"key":"12432_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","volume":"28","author":"JS Dron","year":"2017","unstructured":"Dron, J. S. & Hegele, R. A. Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. Curr. Opin. Lipidol. 28, 161\u2013169. https:\/\/doi.org\/10.1097\/MOL.0000000000000386 (2017).","journal-title":"Curr. Opin. Lipidol."},{"key":"12432_CR7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen, J. C., Boerwinkle, E., Mosley, T. H. Jr. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264\u20131272. https:\/\/doi.org\/10.1056\/NEJMoa054013 (2006).","journal-title":"N Engl. J. Med."},{"key":"12432_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1086\/500615","volume":"78","author":"IK Kotowski","year":"2006","unstructured":"Kotowski, I. K. et al. A spectrum of PCSK9 alleles contributes to plasma levels of Low-Density lipoprotein cholesterol. Am. J. Hum. Genet. 78, 410\u2013422. https:\/\/doi.org\/10.1086\/500615 (2006).","journal-title":"Am. J. Hum. Genet."},{"key":"12432_CR9","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","volume":"55","author":"M Benn","year":"2010","unstructured":"Benn, M., Nordestgaard, B. G., Grande, P., Schnohr, P. & Tybj\u00e6rg-Hansen, A. PCSK9 R46L, Low-Density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and Meta-Analyses. J. Am. Coll. Cardiol. 55, 2833\u20132842. https:\/\/doi.org\/10.1016\/j.jacc.2010.02.044 (2010).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12432_CR10","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.jacl.2018.04.004","volume":"12","author":"JM Mostaza","year":"2018","unstructured":"Mostaza, J. M. et al. R46L polymorphism in the PCSK9 gene: relationship to lipid levels, subclinical vascular disease, and erectile dysfunction. J. Clin. Lipidol. 12, 1039\u20131046e3. https:\/\/doi.org\/10.1016\/j.jacl.2018.04.004 (2018).","journal-title":"J. Clin. Lipidol."},{"key":"12432_CR11","doi-asserted-by":"publisher","first-page":"e001992","DOI":"10.1161\/CIRCGEN.117.001992","volume":"11","author":"J Pott","year":"2018","unstructured":"Pott, J. et al. Genetic regulation of PCSK9 (proprotein convertase subtilisin\/kexin type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes. Circ. Genom Precis Med. 11, e001992. https:\/\/doi.org\/10.1161\/CIRCGEN.117.001992 (2018).","journal-title":"Circ. Genom Precis Med."},{"key":"12432_CR12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/eci.12206","volume":"44","author":"AP van de Woestijne","year":"2014","unstructured":"van de Woestijne, A. P. et al. LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease. Eur. J. Clin. Invest. 44, 184\u2013191. https:\/\/doi.org\/10.1111\/eci.12206 (2014).","journal-title":"Eur. J. Clin. Invest."},{"key":"12432_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/diagnostics11050774","volume":"11","author":"E Zamarron-Licona","year":"2021","unstructured":"Zamarron-Licona, E. et al. Variants of PCSK9 gene are associated with subclinical atherosclerosis and cardiometabolic parameters in mexicans. The GEA project. Diagnostics 11, 774. https:\/\/doi.org\/10.3390\/diagnostics11050774 (2021).","journal-title":"Diagnostics"},{"key":"12432_CR14","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.12659\/MSM.892091","volume":"20","author":"D Han","year":"2014","unstructured":"Han, D. et al. Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations. Med. Sci. Monit. 20, 1758\u20131767. https:\/\/doi.org\/10.12659\/MSM.892091 (2014).","journal-title":"Med. Sci. Monit."},{"key":"12432_CR15","doi-asserted-by":"publisher","first-page":"100242","DOI":"10.1016\/j.jlr.2022.100242","volume":"63","author":"F Bartoli-Leonard","year":"2022","unstructured":"Bartoli-Leonard, F. et al. Elevated lipoprotein(a) as a predictor for coronary events in older men. J. Lipid Res. 63, 100242. https:\/\/doi.org\/10.1016\/j.jlr.2022.100242 (2022).","journal-title":"J. Lipid Res."},{"key":"12432_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/s0735-1097(97)00189-7","volume":"30","author":"DS Celermajer","year":"1997","unstructured":"Celermajer, D. S. Endothelial dysfunction: Does it matter? Is it reversible? J. Am. Coll. Cardiol. 30, 325\u2013333. https:\/\/doi.org\/10.1016\/s0735-1097(97)00189-7 (1997).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12432_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/01.cir.0000025404.78001.d8","volume":"106","author":"JP Halcox","year":"2002","unstructured":"Halcox, J. P. et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106, 653\u2013658. https:\/\/doi.org\/10.1161\/01.cir.0000025404.78001.d8 (2002).","journal-title":"Circulation"},{"key":"12432_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","volume":"115","author":"MW Lorenz","year":"2007","unstructured":"Lorenz, M. W., Markus, H. S., Bots, M. L., Rosvall, M. & Sitzer, M. Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis. Circulation 115, 459\u2013467. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.628875 (2007).","journal-title":"Circulation"},{"key":"12432_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3390\/jcdd8120181","volume":"8","author":"AR Likozar","year":"2021","unstructured":"Likozar, A. R., Blinc, A., Podkraj\u0161ek, K. T. & \u0160ebe\u0161tjen, M. LPA genotypes and haplotypes are associated with lipoprotein(a) levels but not arterial wall properties in stable post-coronary event patients with very high lipoprotein(a) levels. J. Cardiovasc. Dev. Dis. 8, 181. https:\/\/doi.org\/10.3390\/jcdd8120181 (2021).","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"12432_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499\u2013502 (1972).","journal-title":"Clin. Chem."},{"key":"12432_CR21","doi-asserted-by":"publisher","unstructured":"Alley, H., Owens, C. D., Gasper, W. J. & Grenon, S. M. Ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery in clinical research. J. Vis. Exp. https:\/\/doi.org\/10.3791\/52070 (2014).","DOI":"10.3791\/52070"},{"key":"12432_CR22","doi-asserted-by":"publisher","first-page":"451","DOI":"10.23736\/S0392-9590.19.04267-6","volume":"38","author":"L Saba","year":"2019","unstructured":"Saba, L. et al. Global perspective on carotid intima-media thickness and plaque: Should the current measurement guidelines be revisited? Int. Angiol. 38, 451\u2013465. https:\/\/doi.org\/10.23736\/S0392-9590.19.04267-6 (2019).","journal-title":"Int. Angiol."},{"key":"12432_CR23","doi-asserted-by":"publisher","unstructured":"Knuuti, J. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 41, 407\u2013477. Erratum in: Eur. Heart J. 41, 4242 (2020). https:\/\/doi.org\/10.1093\/eurheartj\/ehz425 (2020).","DOI":"10.1093\/eurheartj\/ehz425"},{"key":"12432_CR24","doi-asserted-by":"publisher","unstructured":"Martin, F. J. et al. Ensembl. Nucleic Acids Res. 51, D933\u2013D941. https:\/\/doi.org\/10.1093\/nar\/gkac958 (2023).","DOI":"10.1093\/nar\/gkac958"},{"key":"12432_CR25","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1016\/j.jacc.2019.03.517","volume":"73","author":"M Benn","year":"2019","unstructured":"Benn, M., Tybj\u00e6rg-Hansen, A. & Nordestgaard, B. G. Low LDL cholesterol by PCSK9 variation reduces cardiovascular mortality. J. Am. Coll. Cardiol. 73, 3102\u20133114. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.517 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12432_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/ATVBAHA.116.307995","volume":"37","author":"R Verbeek","year":"2017","unstructured":"Verbeek, R. et al. Carriers of the PCSK9 R46L variant are characterized by an antiatherogenic lipoprotein profile assessed by nuclear magnetic resonance spectroscopy - Brief report. Arterioscler. Thromb. Vasc. Biol. 37, 43\u201348. https:\/\/doi.org\/10.1161\/ATVBAHA.116.307995 (2017).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"12432_CR27","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1373\/clinchem.2011.172932","volume":"58","author":"Z Awan","year":"2012","unstructured":"Awan, Z. et al. Rosuvastatin, proprotein convertase subtilisin\/kexin type 9 concentrations, and LDL cholesterol response: The JUPITER trial. Clin. Chem. 58, 183\u2013189. https:\/\/doi.org\/10.1373\/clinchem.2011.172932 (2012).","journal-title":"Clin. Chem."},{"key":"12432_CR28","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12944-017-0506-6","volume":"16","author":"C Qiu","year":"2017","unstructured":"Qiu, C. et al. What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: A meta-analysis. Lipids Health Dis. 16, 111. https:\/\/doi.org\/10.1186\/s12944-017-0506-6 (2017).","journal-title":"Lipids Health Dis."},{"key":"12432_CR29","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.hlc.2015.10.017","volume":"25","author":"DC Chan","year":"2016","unstructured":"Chan, D. C. et al. Plasma proprotein convertase subtilisin kexin type 9 as a predictor of carotid atherosclerosis in asymptomatic adults. Heart Lung Circ. 25, 520\u2013525. https:\/\/doi.org\/10.1016\/j.hlc.2015.10.017 (2016).","journal-title":"Heart Lung Circ."},{"key":"12432_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40119-017-0092-8","volume":"6","author":"\u0160 Toth","year":"2017","unstructured":"Toth, \u0160. et al. Elevated Circulating PCSK9 concentrations predict subclinical atherosclerotic changes in low risk obese and Non-Obese patients. Cardiol. Ther. 6, 281\u2013289. https:\/\/doi.org\/10.1007\/s40119-017-0092-8 (2017).","journal-title":"Cardiol. Ther."},{"key":"12432_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.athplu.2022.07.001","volume":"50","author":"A Rehberger Likozar","year":"2022","unstructured":"Rehberger Likozar, A. & \u0160ebe\u0161tjen, M. Smoking and diabetes attenuate Bene Fi Cial effects of PSCK9 inhibitors on arterial wall properties in patients with very high lipoprotein (a) levels. Atheroscler. Plus 50, 1\u20139. https:\/\/doi.org\/10.1016\/j.athplu.2022.07.001 (2022).","journal-title":"Atheroscler Plus"},{"key":"12432_CR32","doi-asserted-by":"publisher","first-page":"104513","DOI":"10.1016\/j.mvr.2023.104513","volume":"148","author":"J Schremmer","year":"2023","unstructured":"Schremmer, J. et al. Chronic PCSK9 inhibitor therapy leads to sustained improvements in endothelial function, arterial stiffness, and microvascular function. Microvasc. Res. 148, 104513. https:\/\/doi.org\/10.1016\/j.mvr.2023.104513 (2023).","journal-title":"Microvasc Res."},{"key":"12432_CR33","doi-asserted-by":"publisher","unstructured":"Devesa, A. et al. Cardiac insulin resistance in subjects with metabolic syndrome traits and early subclinical atherosclerosis. Diabetes Care 46, 2050\u20132057. https:\/\/doi.org\/10.2337\/dc23-0871 (2023).","DOI":"10.2337\/dc23-0871"},{"key":"12432_CR34","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00019501-200505000-00007","volume":"16","author":"M Sebestjen","year":"2005","unstructured":"Sebestjen, M., Zegura, B., Videcnik, V. & Keber, I. Determinants of endothelial dysfunction and carotid intima-media thickness in combined hyperlipidemia. Coron. Artery Dis. 16, 175\u2013180. https:\/\/doi.org\/10.1097\/00019501-200505000-00007 (2005).","journal-title":"Coron. Artery Dis."},{"key":"12432_CR35","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/dom.12536","volume":"17","author":"A Sahebkar","year":"2015","unstructured":"Sahebkar, A., Simental-Mend\u00eda, L. E., Guerrero-Romero, F., Golledge, J. & Watts, G. F. Effect of Statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials. Diabetes Obes. Metab. 17, 1042\u20131055. https:\/\/doi.org\/10.1111\/dom.12536 (2015).","journal-title":"Diabetes Obes. Metab."},{"key":"12432_CR36","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1016\/j.jacc.2003.08.066","volume":"43","author":"HD Wu","year":"2004","unstructured":"Wu, H. D. et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J. Am. Coll. Cardiol. 43, 1828\u20131833. https:\/\/doi.org\/10.1016\/j.jacc.2003.08.066 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"12432_CR37","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.atherosclerosis.2015.07.024","volume":"242","author":"S Bos","year":"2015","unstructured":"Bos, S. et al. Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with Familial hypercholesterolemia. Atherosclerosis 242, 226\u2013229. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.024 (2015).","journal-title":"Atherosclerosis"},{"key":"12432_CR38","doi-asserted-by":"publisher","first-page":"14668","DOI":"10.3390\/ijms241914668","volume":"24","author":"YC Chang","year":"2023","unstructured":"Chang, Y. C. et al. Exploring PCSK9 genetic impact on Lipoprotein(a) via dual approaches: association and Mendelian randomization. Int. J. Mol. Sci. 24, 14668. https:\/\/doi.org\/10.3390\/ijms241914668 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"12432_CR39","doi-asserted-by":"publisher","first-page":"159288","DOI":"10.1016\/j.bbalip.2023.159288","volume":"1868","author":"A Roubtsova","year":"2023","unstructured":"Roubtsova, A. et al. Surface LDLR is a major receptor for lipoprotein(a) clearance in male mice lacking PCSK9. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 1868, 159288. https:\/\/doi.org\/10.1016\/j.bbalip.2023.159288 (2023).","journal-title":"Biochim. Biophys. Acta Mol. Cell. Biol. Lipids"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12432-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12432-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12432-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T19:30:56Z","timestamp":1757273456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12432-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12432"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12432-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,23]]},"assertion":[{"value":"6 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Slovenian Ethics Committee for Research in Medicine (KME 0120-357\/2018\/8; date of approval: 23 April 2019 and KME 0120-317\/2021\/3; date of approval: 2 August 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"26753"}}